148 related articles for article (PubMed ID: 29317253)
1. CXCR4 antagonist AMD3100 enhances the response of MDA-MB-231 triple-negative breast cancer cells to ionizing radiation.
Zhou KX; Xie LH; Peng X; Guo QM; Wu QY; Wang WH; Zhang GL; Wu JF; Zhang GJ; Du CW
Cancer Lett; 2018 Apr; 418():196-203. PubMed ID: 29317253
[TBL] [Abstract][Full Text] [Related]
2. Forkhead box C1 boosts triple-negative breast cancer metastasis through activating the transcription of chemokine receptor-4.
Pan H; Peng Z; Lin J; Ren X; Zhang G; Cui Y
Cancer Sci; 2018 Dec; 109(12):3794-3804. PubMed ID: 30290049
[TBL] [Abstract][Full Text] [Related]
3. CXCR4 Protein Epitope Mimetic Antagonist POL5551 Disrupts Metastasis and Enhances Chemotherapy Effect in Triple-Negative Breast Cancer.
Xiang J; Hurchla MA; Fontana F; Su X; Amend SR; Esser AK; Douglas GJ; Mudalagiriyappa C; Luker KE; Pluard T; Ademuyiwa FO; Romagnoli B; Tuffin G; Chevalier E; Luker GD; Bauer M; Zimmermann J; Aft RL; Dembowsky K; Weilbaecher KN
Mol Cancer Ther; 2015 Nov; 14(11):2473-85. PubMed ID: 26269605
[TBL] [Abstract][Full Text] [Related]
4. AZD5438, an inhibitor of Cdk1, 2, and 9, enhances the radiosensitivity of non-small cell lung carcinoma cells.
Raghavan P; Tumati V; Yu L; Chan N; Tomimatsu N; Burma S; Bristow RG; Saha D
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):e507-14. PubMed ID: 22795803
[TBL] [Abstract][Full Text] [Related]
5. Combination of the novel histone deacetylase inhibitor YCW1 and radiation induces autophagic cell death through the downregulation of BNIP3 in triple-negative breast cancer cells in vitro and in an orthotopic mouse model.
Chiu HW; Yeh YL; Wang YC; Huang WJ; Ho SY; Lin P; Wang YJ
Mol Cancer; 2016 Jun; 15(1):46. PubMed ID: 27286975
[TBL] [Abstract][Full Text] [Related]
6. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
[TBL] [Abstract][Full Text] [Related]
7. Silencing of CXCR4 sensitizes triple-negative breast cancer cells to cisplatin.
Liang S; Peng X; Li X; Yang P; Xie L; Li Y; Du C; Zhang G
Oncotarget; 2015 Jan; 6(2):1020-30. PubMed ID: 25544759
[TBL] [Abstract][Full Text] [Related]
8. CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy.
Domanska UM; Timmer-Bosscha H; Nagengast WB; Oude Munnink TH; Kruizinga RC; Ananias HJ; Kliphuis NM; Huls G; De Vries EG; de Jong IJ; Walenkamp AM
Neoplasia; 2012 Aug; 14(8):709-18. PubMed ID: 22952424
[TBL] [Abstract][Full Text] [Related]
9. CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients.
Lefort S; Thuleau A; Kieffer Y; Sirven P; Bieche I; Marangoni E; Vincent-Salomon A; Mechta-Grigoriou F
Oncogene; 2017 Mar; 36(9):1211-1222. PubMed ID: 27669438
[TBL] [Abstract][Full Text] [Related]
10. Knockdown of CAVEOLIN-1 Sensitizes Human Basal-Like Triple-Negative Breast Cancer Cells to Radiation.
Zou M; Li Y; Xia S; Chu Q; Xiao X; Qiu H; Chen Y; Zheng Z; Liu F; Zhuang L; Yu S
Cell Physiol Biochem; 2017; 44(2):778-791. PubMed ID: 29169152
[TBL] [Abstract][Full Text] [Related]
11. Synergistic antitumor effect of NVP-BEZ235 and CAPE on MDA-MB-231 breast cancer cells.
Torki S; Soltani A; Shirzad H; Esmaeil N; Ghatrehsamani M
Biomed Pharmacother; 2017 Aug; 92():39-45. PubMed ID: 28528184
[TBL] [Abstract][Full Text] [Related]
12. Antitumor effect of CXCR4 antagonist AMD3100 on the tumorigenic cell line of BHP10-3 papillary thyroid cancer cells.
Jung YH; Lee DY; Cha W; Kim BH; Sung MW; Kim KH; Ahn SH
Head Neck; 2016 Oct; 38(10):1479-86. PubMed ID: 27061747
[TBL] [Abstract][Full Text] [Related]
13. CXCR4-Targeted and Redox Responsive Dextrin Nanogel for Metastatic Breast Cancer Therapy.
Zhang F; Gong S; Wu J; Li H; Oupicky D; Sun M
Biomacromolecules; 2017 Jun; 18(6):1793-1802. PubMed ID: 28445650
[TBL] [Abstract][Full Text] [Related]
14. Activation of STAT3 and Bcl-2 and reduction of reactive oxygen species (ROS) promote radioresistance in breast cancer and overcome of radioresistance with niclosamide.
Lu L; Dong J; Wang L; Xia Q; Zhang D; Kim H; Yin T; Fan S; Shen Q
Oncogene; 2018 Sep; 37(39):5292-5304. PubMed ID: 29855616
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and validation of novel nitrogen-based chalcone analogs against triple negative breast cancer.
Elkhalifa D; Siddique AB; Qusa M; Cyprian FS; El Sayed K; Alali F; Al Moustafa AE; Khalil A
Eur J Med Chem; 2020 Feb; 187():111954. PubMed ID: 31838326
[TBL] [Abstract][Full Text] [Related]
16. CXCR4 inhibition synergizes with cytotoxic chemotherapy in gliomas.
Redjal N; Chan JA; Segal RA; Kung AL
Clin Cancer Res; 2006 Nov; 12(22):6765-71. PubMed ID: 17121897
[TBL] [Abstract][Full Text] [Related]
17. AMD3100 inhibits epithelial-mesenchymal transition, cell invasion, and metastasis in the liver and the lung through blocking the SDF-1α/CXCR4 signaling pathway in prostate cancer.
Zhu WB; Zhao ZF; Zhou X
J Cell Physiol; 2019 Jul; 234(7):11746-11759. PubMed ID: 30537000
[TBL] [Abstract][Full Text] [Related]
18. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.
Jang NY; Kim DH; Cho BJ; Choi EJ; Lee JS; Wu HG; Chie EK; Kim IA
BMC Cancer; 2015 Mar; 15():89. PubMed ID: 25884663
[TBL] [Abstract][Full Text] [Related]
19. Matrix compliance permits NF-κB activation to drive therapy resistance in breast cancer.
Drain AP; Zahir N; Northey JJ; Zhang H; Huang PJ; Maller O; Lakins JN; Yu X; Leight JL; Alston-Mills BP; Hwang ES; Chen YY; Park CC; Weaver VM
J Exp Med; 2021 May; 218(5):. PubMed ID: 33822843
[TBL] [Abstract][Full Text] [Related]
20. Targeting PI3K and AMPKα Signaling Alone or in Combination to Enhance Radiosensitivity of Triple Negative Breast Cancer.
Johnson J; Chow Z; Napier D; Lee E; Weiss HL; Evers BM; Rychahou P
Cells; 2020 May; 9(5):. PubMed ID: 32438621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
